ReviewAsian journal of pharmaceutical sciences2022
mRNA vaccines: Past, present, future.
Review in Asian journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 69 citations in OpenAlex.
- Self-amplifying mRNA vaccine cocktail against Staphylococcus aureus: A multi-epitope immunoinformatics and structural simulation framework.World journal of microbiology & biotechnology · 2026Article
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- Messenger RNA Nanomedicine: Innovations and Future Directions.Current protein & peptide science · 2026Review
- The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2025Article
- Advances and Strategies in Enhancing mRNA Cancer Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- An immunoinformatics approach in designing high-coverage mRNA multi-epitope vaccine against multivariant SARS-CoV-2.Journal, genetic engineering & biotechnology · 2025Article
- Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.Biological procedures online · 2025Review
- A new era of cancer immunotherapy: vaccines and miRNAs.Cancer immunology, immunotherapy : CII · 2025Review
- The immunogenic potential of an optimized mRNA lipid nanoparticle formulation carrying sequences from virus and protozoan antigens.Journal of nanobiotechnology · 2025Article
- Developing mRNA Nanomedicines with Advanced Targeting Functions.Nano-micro letters · 2025Review
- Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.International journal of molecular sciences · 2025Review
- Q Fever Vaccines: Unveiling the Historical Journey and Contemporary Innovations in Vaccine Development.Vaccines · 2025Review
- mRNA vaccines in the context of cancer treatment: from concept to application.Journal of translational medicine · 2025Review
- A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.Current topics in medicinal chemistry · 2025Review
- Advances and prospects of RNA delivery nanoplatforms for cancer therapy.Acta pharmaceutica Sinica. B · 2025Review
- Development of mRNA rabies vaccines.Human vaccines & immunotherapeutics · 2024Review
- mRNA-based therapeutic strategies for cancer treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- mRNA vaccine development and applications: A special focus on tumors (Review).International journal of oncology · 2024Review
- Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement.Current microbiology · 2024Review
- The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV).Virology journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
mRNA vaccines have emerged as promising alternative platforms to conventional vaccines. Their ease of production, low cost, safety profile and high potency render them ideal candidates for prevention and treatment of infectious diseases, especially in the midst of pandemics. The challenges that face
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.